WallStreetZenWallStreetZen

NYSE: DNA
Ginkgo Bioworks Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DNA

Based on 2 analysts offering 12 month price targets for Ginkgo Bioworks Holdings Inc

Min Forecast
$5.00-51.03%
Avg Forecast
$8.50-16.75%
Max Forecast
$12.00+17.53%

Should I buy or sell DNA stock?

Based on 2 analysts offering ratings for Ginkgo Bioworks Holdings Inc.

Hold
Strong Buy
1 analysts 50%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
1 analysts 50%
Our proven Zen Rating quant model agrees with analyst consensus with a "Hold" rating. Learn More

Be the first to know when Wall Street analysts revise their DNA stock forecasts and price targets.

DNA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-12
lockedlocked$00.00+00.00%2026-01-08

1 of 1

Forecast return on equity

Is DNA forecast to generate an efficient return?

Company
N/A
Industry
92.33%
Market
172.1%

Forecast return on assets

Is DNA forecast to generate an efficient return on assets?

Company
N/A
Industry
27.28%

DNA earnings per share forecast

What is DNA's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$3.95
Avg 2 year Forecast
-$3.34
Avg 3 year Forecast
-$3.21

DNA revenue forecast

What is DNA's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$106.7M-24.49%
Avg 2 year Forecast
$117.6M-16.81%
Avg 3 year Forecast
$299.4M+111.84%
DNA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DNA revenue growth forecast

How is DNA forecast to perform vs Biotechnology companies and vs the US market?

Company
28.43%
Industry
34.13%
Market
13.72%
DNA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DNA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DNA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DNA$10.21$8.50-16.75%Hold
PRME$3.72$9.50+155.38%Buy
FDMT$12.88$30.20+134.47%Strong Buy
IVA$3.55$13.75+287.32%Strong Buy
EIKN$12.74$25.20+97.80%Buy
View Top Biotech Stocks

Ginkgo Bioworks Holdings Stock Forecast FAQ

Is Ginkgo Bioworks Holdings Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSE: DNA) stock is to Hold DNA stock.

Out of 2 analysts, 1 (50%) are recommending DNA as a Strong Buy, 0 (0%) are recommending DNA as a Buy, 0 (0%) are recommending DNA as a Hold, 0 (0%) are recommending DNA as a Sell, and 1 (50%) are recommending DNA as a Strong Sell.

If you're new to stock investing, here's how to buy Ginkgo Bioworks Holdings stock.

What is DNA's earnings growth forecast for 2026-2028?

(NYSE: DNA) Ginkgo Bioworks Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.7%.

Ginkgo Bioworks Holdings's earnings in 2026 is -$304,393,000.On average, 4 Wall Street analysts forecast DNA's earnings for 2026 to be -$257,972,947, with the lowest DNA earnings forecast at -$281,679,205, and the highest DNA earnings forecast at -$234,580,247. On average, 3 Wall Street analysts forecast DNA's earnings for 2027 to be -$218,059,683, with the lowest DNA earnings forecast at -$217,661,204, and the highest DNA earnings forecast at -$220,176,197.

In 2028, DNA is forecast to generate -$209,809,200 in earnings, with the lowest earnings forecast at -$203,577,244 and the highest earnings forecast at -$218,118,475.

What is DNA's revenue growth forecast for 2026-2028?

(NYSE: DNA) Ginkgo Bioworks Holdings's forecast annual revenue growth rate of 28.43% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.13%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.72%.

Ginkgo Bioworks Holdings's revenue in 2026 is $141,311,000.On average, 4 Wall Street analysts forecast DNA's revenue for 2026 to be $6,970,776,435, with the lowest DNA revenue forecast at $6,408,201,918, and the highest DNA revenue forecast at $7,627,287,569. On average, 3 Wall Street analysts forecast DNA's revenue for 2027 to be $7,679,547,162, with the lowest DNA revenue forecast at $7,343,126,033, and the highest DNA revenue forecast at $8,100,890,129.

In 2028, DNA is forecast to generate $19,555,539,626 in revenue, with the lowest revenue forecast at $18,974,804,901 and the highest revenue forecast at $20,330,288,089.

What is DNA's forecast return on assets (ROA) for 2026-2029?

(NYSE: DNA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 27.28%.

What is DNA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year DNA price target, the average DNA price target is $8.50, with the highest DNA stock price forecast at $12.00 and the lowest DNA stock price forecast at $5.00.

On average, Wall Street analysts predict that Ginkgo Bioworks Holdings's share price could fall to $8.50 by Mar 12, 2027. The average Ginkgo Bioworks Holdings stock price prediction forecasts a potential downside of 16.75% from the current DNA share price of $10.21.

What is DNA's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: DNA) Ginkgo Bioworks Holdings's current Earnings Per Share (EPS) is -$5.36. On average, analysts forecast that DNA's EPS will be -$3.95 for 2026, with the lowest EPS forecast at -$4.31, and the highest EPS forecast at -$3.59. On average, analysts forecast that DNA's EPS will be -$3.34 for 2027, with the lowest EPS forecast at -$3.33, and the highest EPS forecast at -$3.37. In 2028, DNA's EPS is forecast to hit -$3.21 (min: -$3.12, max: -$3.34).

What is DNA's forecast return on equity (ROE) for 2026-2029?

(NYSE: DNA) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.